Literature DB >> 7539408

Molecular analysis of neutralizing epitopes on outer surface proteins A and B of Borrelia burgdorferi.

J Ma1, C Gingrich-Baker, P M Franchi, P Bulger, R T Coughlin.   

Abstract

The neutralizing epitopes of the major outer surface proteins A and B (OspA and OspB) of Borrelia burgdorferi B31 were investigated by epitope mapping using overlapping synthetic peptides, encompassing full-length OspA and OspB, and antiborrelial monoclonal antibodies (MAbs). OspA MAb N4B12 and OspB MAbs N5G5, W7C2, and P4D1 displayed a complement-independent antiborrelial activity, and complement failed to enhance the antiborrelial activity, as measured by a sensitive colorimetric assay. A combination of N4B12 with N5G5 displayed a higher antiborrelial activity than did the MAbs individually. OspA MAbs B3G11 and L3B5, however, exhibited a significant antiborrelial activity only in the presence of complement. Epitope mapping showed that B3G11 bound to one OspA synthetic peptide with the sequence of amino acids 247 to 256 (QYDSNGTKLE) and produced more than sixfold-higher reactivity than with other sequences, as measured by an enzyme-linked immunosorbent assay. OspB MAb N5G5 bound to an OspB peptide with the sequence of amino acids 211 to 220 (TLKREIEKDG), yielding at least threefold-higher reactivity than with other sequences. These two peptide sequences were found to contain neutralizing epitopes. Other MAbs had weak binding activities with the synthetic peptides, and their specific epitopes remain to be further analyzed. Thus, this study demonstrated both complement-independent and complement-dependent antiborrelial MAbs and identified the linear epitopes on OspA and OspB capable of inducing neutralizing antibody responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539408      PMCID: PMC173289          DOI: 10.1128/iai.63.6.2221-2227.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Treating erythema chronicum migrans of Lyme disease.

Authors:  B W Berger
Journal:  J Am Acad Dermatol       Date:  1986-09       Impact factor: 11.527

2.  Biologic activities of peromyscus 7S-gamma-1 and 7S-gamma-2 globulins.

Authors:  J Coe; L Peel; R F Smith
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

3.  Lyme disease-a tick-borne spirochetosis?

Authors:  W Burgdorfer; A G Barbour; S F Hayes; J L Benach; E Grunwaldt; J P Davis
Journal:  Science       Date:  1982-06-18       Impact factor: 47.728

4.  Normal human B lymphocytes and mononuclear cells respond to the mitogenic and cytokine-stimulatory activities of Borrelia burgdorferi and its lipoprotein OspA.

Authors:  K F Tai; Y Ma; J J Weis
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

5.  Passive immunization of hamsters against experimental infection with the Lyme disease spirochete.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

6.  Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.

Authors:  G Baranton; D Postic; I Saint Girons; P Boerlin; J C Piffaretti; M Assous; P A Grimont
Journal:  Int J Syst Bacteriol       Date:  1992-07

7.  Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway.

Authors:  S K Kochi; R C Johnson
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

8.  A short-duration polyethylene glycol fusion technique for increasing production of monoclonal antibody-secreting hybridomas.

Authors:  R D Lane
Journal:  J Immunol Methods       Date:  1985-08-02       Impact factor: 2.303

9.  A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein.

Authors:  A Sadziene; M Jonsson; S Bergström; R K Bright; R C Kennedy; A G Barbour
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Monoclonal antibodies for identification of Borrelia afzelii sp. nov. associated with late cutaneous manifestations of Lyme borreliosis.

Authors:  M M Canica; F Nato; L du Merle; J C Mazie; G Baranton; D Postic
Journal:  Scand J Infect Dis       Date:  1993
View more
  20 in total

1.  Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

Authors:  S M Callister; D A Jobe; R F Schell; C S Pavia; S D Lovrich
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

2.  Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting.

Authors:  J R Creson; L C Lim; N J Glowacki; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

3.  Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present.

Authors:  M Solé; C Bantar; K Indest; Y Gu; R Ramamoorthy; R Coughlin; M T Philipp
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Antibody Binding to the O-Specific Antigen of Pseudomonas aeruginosa O6 Inhibits Cell Growth.

Authors:  Gabrielle Richard; C Roger MacKenzie; Kevin A Henry; Evgeny Vinogradov; J Christopher Hall; Greg Hussack
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro.

Authors:  Erik L Munson; Dean T Nardelli; K H Kevin Luk; Monica C Remington; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses.

Authors:  Fang Ting Liang; Jun Yan; M Lamine Mbow; Steven L Sviat; Robert D Gilmore; Mark Mamula; Erol Fikrig
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  OspB antibody prevents Borrelia burgdorferi colonization of Ixodes scapularis.

Authors:  Erol Fikrig; Utpal Pal; Manchuan Chen; John F Anderson; Richard A Flavell
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

8.  C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Authors:  Dean A Jobe; Steven D Lovrich; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

9.  Effect of complement component C3 deficiency on experimental Lyme borreliosis in mice.

Authors:  Matthew B Lawrenz; R Mark Wooten; James F Zachary; Scott M Drouin; Janis J Weis; Rick A Wetsel; Steven J Norris
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.